Details

Autor(en) / Beteiligte

• Griessbach, Alexandra
• Chammartin, Frédérique
• Abela, Irene A
• Amico, Patrizia
• Stoeckle, Marcel P
• Eichenberger, Anna L
• Hasse, Barbara
• Braun, Dominique L
• Schuurmans, Macé M
• Müller, Thomas F
• Tamm, Michael
• Audigé, Annette
• Mueller, Nicolas J
• Rauch, Andri
• Günthard, Huldrych F
• Koller, Michael T
• Trkola, Alexandra
• Epp, Selina
• Amstutz, Alain
• Schönenberger, Christof M
• Taji Heravi, Ala
• Kusejko, Katharina
• Bucher, Heiner C
• Briel, Matthias
• Speich, Benjamin

Titel

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)

Ist Teil von

• Open forum infectious diseases, 2023-04, Vol.10 (4), p.ofad150-ofad150

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Abstract Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%–100.0%]) in individuals with different levels of immunosuppression (difference, −2.8% [95% CI, −6.8% to 1.3%]). The extension of the COrona VaccinE tRiAL pLatform trial (COVERALL) showed the non-inferiority in antibody response of the third Moderna mRNA-1273 vaccine dose compared to the third Pfizer-BioNTech BNT162b2 vaccine in individuals living with HIV and solid organ transplant recipients.